The effect of liraglutide on weight loss in women with polycystic ovary syndrome: An observational study

Frontiers in Endocrinology

Volumn 5, Issue AUG, 2014, Pages

  Rasmussen, Christina B ^a   Lindenberg, Svend ^a  

^a Psychiatric Center Copenhagen   (Denmark)

Author keywords

GLP 1 analogs; Liraglutide; Obesity; Polycystic ovary syndrome; Weight loss

Indexed keywords

LIRAGLUTIDE; METFORMIN;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; ARTICLE; BODY MASS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE INCREASE; EVALUATION AND FOLLOW UP; EXERCISE; FEMALE; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MIDDLE AGED; NAUSEA AND VOMITING; OBSERVATIONAL STUDY; OVARY POLYCYSTIC DISEASE; PRURITUS; SEDENTARY LIFESTYLE; WEIGHT CHANGE; WEIGHT REDUCTION; YOUNG ADULT;

EID: 84987834829     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2014.00140     Document Type: Article

References (29)

1. Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril (2012) 97:28-38. doi: 10.1016/j.fertnstert.2011.09.024
2. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod (2010) 25:544-51. doi:10.1093/humrep/dep399
3. Broekmans FJ, Knauff EA, Valkenburg O, Laven JS, Eijkemans MJ, Fauser BC. PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors. BJOG (2006) 113:1210-7. doi:10.1111/j.1471-0528.2006.01008.x
4. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod (2004) 19:41-7. doi:10.1093/humrep/deh098
5. Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord (2002) 26:883-96. doi:10.1038/sj.ijo/0801994
6. Salley KE, Wickham EP, Cheang KI, Essah PA, Karjane NW, Nestler JE. Glucose intolerance in polycystic ovary syndrome-a position statement of the androgen excess society. J Clin Endocrinol Metab (2007) 92:4546-56. doi:10.1210/jc.2007-1549
7. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab (1999) 84:165-9. doi:10.1210/jc.84.1.165
8. DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril (2005) 83:1454-60. doi:10.1016/j.fertnstert.2004.11.070
9. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet (2007) 370:685-97. doi:10.1016/S0140-6736(07)61345-2
10. Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism (2003) 52:908-15. doi:10.1016/S0026-0495(03)00104-5
11. Goverde AJ, van Koert AJ, Eijkemans MJ, Knauff EA, Westerveld HE, Fauser BC, et al. Indicators for metabolic disturbances in anovulatory women with polycystic ovary syndrome diagnosed according to the Rotterdam consensus criteria. Hum Reprod (2009) 24:710-7. doi:10.1093/humrep/den433
12. Thomson RL, Buckley JD, Noakes M, Clifton PM, Norman RJ, Brinkworth GD. The effect of a hypocaloric diet with and without exercise training on body composition, cardiometabolic risk profile, and reproductive function in overweight and obese women with polycystic ovary syndrome. J Clin Endocrinol Metab (2008) 93:3373-80. doi:10.1210/jc.2008-0751
13. Stamets K, Taylor DS, Kunselman A, Demers LM, Pelkman CL, Legro RS. A randomized trial of the effects of two types of short-term hypocaloric diets on weight loss in women with polycystic ovary syndrome. Fertil Steril (2004) 81:630-7. doi:10.1016/j.fertnstert.2003.08.023
14. Tolino A, Gambardella V, Caccavale C, D'Ettore A, Giannotti F, D'Antò V, et al. Evaluation of ovarian functionality after a dietary treatment in obese women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol (2005) 119:87-93. doi:10.1016/j.ejogrb.2004.06.043
15. Kuchenbecker WK, Groen H, van Asselt SJ, Bolster JH, Zwerver J, Slart RH, et al. In women with polycystic ovary syndrome and obesity, loss of intra-abdominal fat is associated with resumption of ovulation. Hum Reprod (2011) 26:2505-12. doi:10.1093/humrep/der229
16. Bode B. An overview of the pharmacokinetics, efficacy and safety of liraglutide. Diabetes Res Clin Pract (2012) 97:27-42. doi:10.1016/j.diabres.2011.12.015
17. Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ (2012) 344:d7771. doi:10.1136/bmj.d7771
18. Jensterle SM, Kocjan T, Pfeifer M, Kravos NA, Janez A. Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. Eur J Endocrinol (2014) 170:451-9. doi:10.1530/EJE-13-0797
19. Torekov SS, Madsbad S, Holst JJ. Obesity-an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential. Obes Rev (2011) 12:593-601. doi:10.1111/j.1467-789X.2011.00860.x
20. Kahal H, Atkin SL, Sathyapalan T. Pharmacological treatment of obesity in patients with polycystic ovary syndrome. J Obes (2011) 2011:402052. doi:10.1155/2011/402052
21. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet (2009) 373:473-81. doi:10.1016/S0140-6736(08)61246-5
22. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care (2009) 32:84-90. doi:10.2337/dc08-1355
23. Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet (2009) 374:1606-16. doi:10.1016/S0140-6736(09)61375-1
24. Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) (2011) 36:843-54. doi:10.1038/ijo.2011.158
25. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet (2009) 374:39-47. doi:10.1016/S0140-6736(09)60659-0
26. Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab (2008) 93:2670-8. doi:10.1210/jc.2008-0115
27. Crosignani PG, Colombo M, Vegetti W, Somigliana E, Gessati A, Ragni G. Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Hum Reprod (2003) 18:1928-32. doi:10.1093/humrep/deg367
28. Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab (1999) 84:1470-4. doi:10.1210/jc.84.4.1470
29. Astrup A, Rossner S, van Gaal L, Rasmussen MF. Liraglutide for weight loss in obese people. Lancet (2010) 375:552-3. doi:10.1016/S0140-6736(10)60227-9